Autopsy report · NCT05009953
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Cause of deathFunding or business
“Internal strategy change. Not related to safety concerns.”
Life of this trial
- Ran for about 1 year 4 months before it stopped.
- 17 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Advanced Biliary Tract Cancer; Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Gallbladder Carcinoma
- Interventions
- Irinotecan Liposome Injection; SG001; Fluorouracil; Leucovorin
- Participants
- 17
- Sites
- 1
- Countries
- China
Trials that died the same way
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
“An internal business decision, not based on safety or regulatory considerations.” - Study of Poziotinib in Japanese Patients With NSCLC
“Business decision, not related to safety.” - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants
“internal company decision; not safety related” - A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
“Internal company decision (non-safety related)” - Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
“Decision based on strategic determination; not safety.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.